The U.S. Food and Drug Administration today approved Otarmeni (lunsotogene parvec-cwha), the first-ever dual adeno-associated virus (AAV) vector-based gene therapy. Otarmeni is indicated for the ...
The U.S. Food and Drug Administration today approved Otarmeni (lunsotogene parvec-cwha), the first-ever dual adeno-associated virus (AAV) vector-based gene therapy. Otarmeni ...
Boston)—Aedes aegypti, commonly known as the yellow fever mosquito, is a highly adapted, invasive mosquito species recognized as a major global ...
Approval in severe-to-profound and profound OTOF-related hearing loss is based on pivotal results of the CHORD trial demonstrating 80% of participants achieved or surpassed a hearing level meeting the ...
The CDC is reporting that ER visits for tick bites are higher than usual. The CDC says that, according to its Bite Tracker, ...
Turkey’s trajectory is not dependent on the outcome of the Iranian case - it is a function of its desire to claim leadership ...
The Big Apple is about to be bled dry — and not just because of ferocious tax hikes. This spring and summer, NYC could see an ...
Arras Minerals Corp. (TSXV: ARK) (OTCQB: ARRKF) ("Arras" or "Arras Minerals" or "the Company") is pleased to report the first ...
Approval in severe-to-profound and profound OTOF -related hearing loss is based on pivotal results of the CHORD trial demonstrating 80% of ...
Approved Thursday via the FDA's Commissioner’s National Priority Voucher program, Otarmeni is the first gene therapy for ...
The FDA has granted an accelerated approval for Otarmeni (lunsotogene parvec-cwha), the first gene therapy to treat patients ...
Mythos combined four separate low-severity bugs into a complete browser sandbox escape. Traditional scanners evaluate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results